Ferroptosis
抑制剂选择性比较
Ferroptosis产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1)是一种有效的选择性的ferroptosis抑制剂，EC50为60 nM。 |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1是一种有效的ferroptosis抑制剂，IC50为22 nM。 |
(D) Indicated NRF2 knockdown HCC cells were treated with erastin (10 μM) and sorafenib (5 μM) with or without indicated inhibitors (ferrostatin-1, 1 μM; liproxstatin-1, 100 nM; ZVAD-FMK, 10 μM; necrostatin-1, 10 μM; necrosulfonamide, 0.5 μM) for 24 hours, and cell viability was assayed (n 5 3, *P < 0.05). Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. |
|
| S8792New |
UAMC-3203UAMC-3203是ferroptosis抑制剂，在IMR-32神经母细胞瘤细胞中IC50为10 nM。 |
||
| S7242 |
ErastinErastin是一种ferroptosis激活剂，通过作用于线粒体VDAC而起作用，选择性作用于携带致癌基因RAS的肿瘤细胞。 |
Western blot analysis indicated protein expression in PDAC cells following treatment with erastin (2.5-40 μmol/L) for 24 hours (n=3, * P < 0.05 vs. untreated group) |
|
| S8254 |
FIN56FIN56是ferroptosis的特异性诱导剂。 |
||
| S8155 |
RSL3RSL3是一种ferroptosis的激活剂，不依赖于VDAC，对携带致瘤性RAS的肿瘤细胞具有选择性。它结合并使GPX4失活，介导GPX4所调节的铁死亡。 |
(D) Representative western blot and (E) densitometry showing protein levels of HO-1 in HO-1+/+ PTCs treated with RSL3 over time. Data shown represent the Mean ± SEM of three independent experiments performed each time in triplicate; * = p<0.05, ** = p<0.01 compared to lower concentration at each time point. |
|
| S8877New |
Imidazole ketone erastinImidazole ketone erastin (IKE)是一种有效的、代谢稳定的、选择性system xc–抑制剂以及ferroptosis诱导剂。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1)是一种有效的选择性的ferroptosis抑制剂，EC50为60 nM。 |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1是一种有效的ferroptosis抑制剂，IC50为22 nM。 |
(D) Indicated NRF2 knockdown HCC cells were treated with erastin (10 μM) and sorafenib (5 μM) with or without indicated inhibitors (ferrostatin-1, 1 μM; liproxstatin-1, 100 nM; ZVAD-FMK, 10 μM; necrostatin-1, 10 μM; necrosulfonamide, 0.5 μM) for 24 hours, and cell viability was assayed (n 5 3, *P < 0.05). Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. |
|
| S8792New |
UAMC-3203UAMC-3203是ferroptosis抑制剂，在IMR-32神经母细胞瘤细胞中IC50为10 nM。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7242 |
ErastinErastin是一种ferroptosis激活剂，通过作用于线粒体VDAC而起作用，选择性作用于携带致癌基因RAS的肿瘤细胞。 |
Western blot analysis indicated protein expression in PDAC cells following treatment with erastin (2.5-40 μmol/L) for 24 hours (n=3, * P < 0.05 vs. untreated group) |
|
| S8254 |
FIN56FIN56是ferroptosis的特异性诱导剂。 |
||
| S8155 |
RSL3RSL3是一种ferroptosis的激活剂，不依赖于VDAC，对携带致瘤性RAS的肿瘤细胞具有选择性。它结合并使GPX4失活，介导GPX4所调节的铁死亡。 |
(D) Representative western blot and (E) densitometry showing protein levels of HO-1 in HO-1+/+ PTCs treated with RSL3 over time. Data shown represent the Mean ± SEM of three independent experiments performed each time in triplicate; * = p<0.05, ** = p<0.01 compared to lower concentration at each time point. |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S8877New |
Imidazole ketone erastinImidazole ketone erastin (IKE)是一种有效的、代谢稳定的、选择性system xc–抑制剂以及ferroptosis诱导剂。 |
沪公网安备 31011502012800号